FDA expands use of antibiotic; EC OKs Xtandi; Lyme disease debate grows;

@FierceBiotech: Troubled AstraZeneca models a new industry R&D tie-up as setbacks mount. Story | Follow @FierceBiotech

 @JohnCFierce: Sandoz bulls ahead with full slate of PhIII biosimilar studies. News | Follow @JohnCFierce

@RyanMFierce: PFE shares software for biotech drug research with pharma rivals like GSK, Roche and others. Story | Follow @RyanMFierce

 @EmilyMFierce: Our special ADA 2013 issue, via @RyanMFierce: Here | Follow @EmilyMFierce

> The FDA expanded the approved use of Theravance's ($THRX) antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Release

> The EC has approved Xtandi for the second-line treatment of prostate cancer. The treatment is marketed by Astellas and Medivation ($MDVN). Story

Medical Device News

 @FierceMedDev: Edwards wins Japanese nod for next-gen Sapien valve. Story | Follow @FierceMedDev

 @DamianFierce: Miss our ADA 2013 coverage? Diabetes news from Medtronic and J&J. | Follow @DamianFierce

 @MichaelGFierce: FDA approved Lombard's Aorflex delivery system, used with its Aorfix stent. Looking to launch this year. More | Follow @MichaelGFierce

> Medtronic leaps toward artificial pancreas with MiniMed study. Story

> J&J's Animas reveals positive artificial pancreas data. Article

Pharma News

 @FiercePharma: CX, that's 7 trials of 5 biosims for Novartis ... Novartis starts PhIII trial of biosimilar of Amgen's Enbrel. Report | Follow @FiercePharma

 @EricPFierce: Has down-home Paula become the 'Deen' of bad publicity for Novo Nordisk? Item | Follow @EricPFierce

 @CarlyHFierce: Shoutout to FierceBiotech in First Manhattan's letter to Vivus shareholders. Letter | Story | Follow @CarlyHFierce

> Russia's Pharmstandard eyes buyers for $2.5B OTC drug business. More

> Proxy challenger scoffs at Vivus as annual meeting nears. Report

> Reported Form 483 may explain Ranbaxy not getting Diovan to market. Story

CRO News

> Icon, Clintec launch grad programs for clinical research. Article

> CRS signs on with Bayer for early trials. Story

> Novotech reaches into Hong Kong, Philippines. News

> inVentiv taps PatientsLikeMe for trial recruitment. Report

Biotech IT News

> Roche designs online software for sequencing business. Story

> FDA taps India's GVK for database support in drug recycling. More

> Pfizer shares software for biotech drug research with pharma rivals. News

> Scientists follow 'Facebook' strategy to corral cancer Big Data. Story

> PatientsLikeMe seals CRO deal for online trial recruitment. Article

And Finally… As new cases of Lyme disease continue to mount, there's a growing argument over the best way to treat it. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.